A new study published in the journal of The Lancet showed that, with no new safety issues, gepotidacin showed no inferiority ...

EAGLE-1 trial data shows gepotidacin’s potential in treating gonorrhoea, for which no new antibiotics have been approved since the 1990s.

An oral dose of zoliflodacin – vying to become the first in the new class of bacterial ... to ceftriaxone and azithromycin, with no cross-resistance with other antibiotics.

GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea. In the EAGLE-1 ...

For uncomplicated urogenital gonorrhea, gepotidacin, which inhibits bacterial DNA replication, is noninferior to ceftriaxone ...

Medicare Part D may typically cover most outpatient prescription medications. These include antibiotics like azithromycin. Learn more here.

UTIs are the cause of roughly 8 million emergency room visits and 100,000 hospitalizations in the US each year, GSK said.

Antibiotic-resistant illnesses, the World Health Organization says they are a global health concern, but the discovery of a ...

Today, only one oral antibiotic is left: the macrolide, azithromycin. And this medicine might not work for much longer. The 2022 study found mutations that confer resistance to azithromycin are ...

Dermatitis. 2007;18(2):63-77. Gonçalo and colleagues [16] patch-tested 66 patients (aged 12 to 83 years) with a history of a maculopapular rash to antibiotics (58%), antiepileptics (25% ...

The ideal negative control is a patient with a recent history (6 weeks to 6 months) of a cutaneous drug eruption whose cause has been identified. For example, if the control patient has a history ...